Cargando…

P096: Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin’ s lymphoma.

Detalles Bibliográficos
Autores principales:	Linderoth, Johan, Freyhult, Eva, Andreasson, Ellinor, Johansson, Ann-Sofie, Andersson, Anne, Glimelius, Ingrid, Enblad, Gunilla, Molin, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Radiotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621546/ http://dx.doi.org/10.1097/01.HS9.0000890952.23394.2d

Ejemplares similares

P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients
por: Goldkuhl, Christina, et al.
Publicado: (2022)

P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
por: Oertel, Michael, et al.
Publicado: (2022)

P094: Long-term outcomes of bulky classic Hodgkin lymphoma managed with a PET-adapted approach demonstrate excellent outcomes in PET-negative cases
por: Kim, Jowon Laura, et al.
Publicado: (2022)

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
por: Jones, David, et al.
Publicado: (2022)

T082: AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients
por: Övergaard, Ninja, et al.
Publicado: (2022)

High risk of cardiovascular side effects after treatment of Hodgkin’s lymphoma – is there a need for intervention in long-term survivors?
por: Andersson, Anne, et al.
Publicado: (2021)

Positional Accuracy of Treating Multiple Versus Single Vertebral Metastases With Stereotactic Body Radiotherapy
por: Chang, Joe H., et al.
Publicado: (2016)

Dosimetric Comparison and Evaluation of 4 Stereotactic Body Radiotherapy Techniques for the Treatment of Prostate Cancer
por: Seppälä, Jan, et al.
Publicado: (2016)

Changes in Tumor Volumes and Spatial Locations Relative to Normal Tissues During Cervical Cancer Radiotherapy Assessed by Cone Beam Computed Tomography
por: Chen, Wenjuan, et al.
Publicado: (2017)

Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach
por: Boldrini, Luca, et al.
Publicado: (2018)

A snapshot on radiotherapy for head and neck cancer patients during the COVID-19 pandemic: a survey of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) head and neck working group
por: De Felice, Francesca, et al.
Publicado: (2020)

Weekly hypofractionated radiation therapy in elderly non-resectable cutaneous squamous cell carcinoma of the head and neck region
por: De Felice, Francesca, et al.
Publicado: (2020)

Impact of COVID-19 on workload burden of a complex radiotherapy facility
por: Francolini, Giulio, et al.
Publicado: (2021)

Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model
por: Cellini, Francesco, et al.
Publicado: (2021)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

ESTRO vision 2030: the young Italian Association of Radiotherapy and Clinical Oncology (yAIRO) commitment statement
por: De Felice, Francesca, et al.
Publicado: (2021)

Impact on mental health of the COVID-19 pandemic in a radiation oncology department
por: Caliandro, Morena, et al.
Publicado: (2022)

Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis
por: Francolini, Giulio, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy (SABR) lung fractionations locally in the COVID-19 era and the impact on dosimetry, resources, early toxicities, and the environment
por: Phelps, Lyndsey, et al.
Publicado: (2021)

EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates
por: Lancellotta, Valentina, et al.
Publicado: (2022)

The impact of particle radiotherapy on the functioning of cardiac implantable electronic devices: a systematic review of in vitro and in vivo studies according to PICO criteria
por: Barcellini, Amelia, et al.
Publicado: (2022)

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)
por: Francolini, Giulio, et al.
Publicado: (2022)

P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
por: Oertel, Michael, et al.
Publicado: (2022)

P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
por: Oertel, Michael, et al.
Publicado: (2022)

Magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) for oligometastatic patients: a single-center experience
por: Chiloiro, Giuditta, et al.
Publicado: (2023)

Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS)
por: Jeyin, Nidhish, et al.
Publicado: (2023)

Pattern of care for re-irradiation in locally recurrent rectal cancer: a national survey on behalf of the AIRO gastrointestinal tumors study group
por: Mantello, Giovanna, et al.
Publicado: (2023)

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
por: Hollander, Peter, et al.
Publicado: (2018)

P045: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
por: Ulfstedt, Johan Mattsson, et al.
Publicado: (2022)

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
por: Lagerlöf, Ingemar, et al.
Publicado: (2022)

Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
por: Gholiha, Alex Reza, et al.
Publicado: (2021)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT)
por: Murray, Louise J., et al.
Publicado: (2014)

30 day mortality in adult palliative radiotherapy – A retrospective population based study of 14,972 treatment episodes
por: Spencer, Katie, et al.
Publicado: (2015)

Uncertainties in estimating heart doses from 2D-tangential breast cancer radiotherapy
por: Lorenzen, Ebbe L., et al.
Publicado: (2016)

Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer
por: Leszczynska, Katarzyna B., et al.
Publicado: (2016)

Real‐world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 years
por: Wahlin, Björn Engelbrekt, et al.
Publicado: (2021)

Dosimetric Comparison of Postmastectomy Radiotherapy Plans for Synchronous Bilateral Breast Cancer, Including Regional Lymph Node Irradiation
por: Wu, Xiuxiu, et al.
Publicado: (2023)

Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma
por: Mattsson Ulfstedt, Johan, et al.
Publicado: (2021)

Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma
por: Andersson, A, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_r8lub1ej47i4288ath5t2eafpp